An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Calquence

Chemical Nameacalabrutinib
Dosage FormCapsule (oral; 100 mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyAstraZeneca
Approval Year2017

Indication

  • Calquence is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
  • Calquence is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Last updated on 2/3/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Calquence (acalabrutinib) Prescribing Information.2019AstraZeneca
Document TitleYearSource
Phramacoeconomic report: acalabrutinib (calquence).2020CADTH
Clinical report: acalabrutinib (calquence).2020CADTH
Acalabrutinib for treating chronic lymphocytic leukaemia.2020The School of Health and Related Research, The University of Sheffield
Document TitleYearSource
Comparative efficacy of acalabrutinib in frontline treatment of chronic lymphocytic leukemia: a systematic review and network meta-analysis.2020Clinical Therapeutics
Comparison between venetoclax-based and bruton tyrosine kinase inhibitor-based therapy as upfront treatment of chronic lymphocytic leukemia (CLL): a systematic review and network meta-analysis.2020Clinical Lymphoma, Myeloma and Leukemia